Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis.
In a trial lasting six months disodium cromoglycate (800 mg daily), sulphasalazine (2 g daily), and these two agents in combination were compared in 120 patients as maintenance treatment for ulcerative colitis. Relapse was defined as recurrence of colitic symptoms accompanied by sigmoidoscopic evidence of inflammation. The patients receiving disodium cromoglycate had a much higher relapse-rate than those taking sulphasalazine and the results with the two agents combined were little different from those with sulphasalazine alone. Disodium cromoglycate in the dose employed is greatly inferior to sulphasalazine as maintenance treatment for the prevention of relapse in ulcerative colitis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004804:Eosinophils / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012007:Rectum / Q000473:pathology; D012008:Recurrence; D012812:Sigmoidoscopy; D012460:Sulfasalazine / Q000008:administration & dosage*; D013997:Time Factors
D012460:Sulfasalazine; D004205:Cromolyn Sodium